Observational Study on Mortality and Outcome of Patients Hospitalized for Subarachnoid Hemorrhage of Aneurysmal Origin in Martinique Between 2013 and 2021 (HSA Rankin)

The aim of our study is to analyze mortality and sequelae of subarachnoid hemorrhage of aneurysmal origin in hospitalized patients in Martinique. Predictive factors of poor prognosis will also be analyzed.

Study Overview

• Status: Recruiting
• Conditions: Subarachnoid Hemorrhage of Aneurysmal Cause
• Intervention / Treatment: Other: Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin

Detailed Description

Subarachnoid hemorrhage is an uncommon pathology in the general population, with a worldwide incidence of 9 per 100,000 people/year, but with a non-negligible risk of sequelae in terms of impairments, activity limitations and participation restrictions of around 30%. Mortality remains high at 40%, despite increasingly specialized care.

In addition, there are a number of objective, rapid assessment scores for autonomy and impairments, notably the modified Rankin score, which is not specific to subarachnoid hemorrhage, but which enables the study of patients' perceived quality of life. Certain factors predictive of bad patient outcome are known in the literature, but have been little studied in the population of Martinique.

• Study Type: Observational
• Enrollment (Estimated): 122

Contacts and Locations

• Study Contact: Name: Marie SABIA, PhD; Phone Number: +596 0596551054; Email: marie.sabia@chu-martinique.fr
• Study Contact Backup: Name: Pauline PICHOIS; Email: paulinep13@live.fr

Study Locations

• Martinique
  • Fort-de-France, Martinique, 97261
    • Recruiting
    • University Hospital Center of Martinique
    • Contact: Yann MOPSUS, MSc; Phone Number: 0596553584; Email: yann.mopsus@chu-martinique.fr
    • Contact: Marie SABIA, PhD
    • Contact: Pauline PICHOIS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients hospitalized in Martinique for subarachnoid hemorrhage of aneurysmal origin

Description

Inclusion Criteria:

• Adult (≥18 years) patients,
• Admitted to University Hospital of Martinique with subarachnoid hemorrhage of aneurysmal origin between 01/01/2013 and 31/12/2021,
• Informed patient/next-of-kin/treating physician consent for research participation.

Exclusion Criteria:

• Other causes of subarachnoid hemorrhage of non-aneurysmal origin (traumatic, arteriovenous malformation, cerebral tumor, cerebral thrombophlebitis).

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

SAH of aneurysmal origin in hospitalized patients in Martinique between 2013 and 2021

Other: Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin; During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate mortality in patients hospitalized for subarachnoid hemorrhage of aneurysmal origin over a 9-year period (2013-2021) in Martinique.	Mortality of subarachnoid hemorrhage of aneurysmal origin.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the clinical outcome of these patients.	Patient's clinical outcome (mortality, impairment of patient autonomy, impairment of patient's level of dependece), assessed with the modified Rankin score at discharge and at a distance from hospitalization (minimum delay: 2.5 years).	6 months
Analyze the factors associated with a significant impairment of autonomy and/or dependence.	Predictive factors associated with significant impairment of patient autonomy and/or dependence (modified Rankin score = 4 or 5): age, degree of consciousness at the time of treatment (WFNS score), amount of blood in the meningeal spaces (Fisher score), aneurysm size	6 months
Analyze the factors associated with death.	Predictive factors associated with death (modified Rankin score = 6): age, degree of consciousness at the time of treatment (WFNS score), amount of blood in the meningeal spaces (Fisher score), aneurysm size.	6 months
Analyze the factors associated with a poor prognosis (death AND/OR significant impairment of autonomy/dependence).	Predictive factors associated with a poor prognosis (modified Rankin score ≥ 4: death AND/OR impaired patient autonomy and/or dependence): age, degree of consciousness at the time of treatment (WFNS score), amount of blood in the meningeal spaces (Fisher score), aneurysm size.	6 months

Collaborators and Investigators

• Sponsor: University Hospital Center of Martinique

Study record dates

Study Major Dates

• Study Start (Actual): July 19, 2024
• Primary Completion (Actual): December 31, 2024
• Study Completion (Estimated): April 1, 2025

Study Registration Dates

• First Submitted: July 24, 2024
• First Submitted That Met QC Criteria: July 24, 2024
• First Posted (Actual): July 29, 2024

Study Record Updates

• Last Update Posted (Actual): March 31, 2025
• Last Update Submitted That Met QC Criteria: March 26, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Mortality; SAH (Subarachnoid Hemorrhage); Ruptured intracranial aneurysm; Modified Rankin score; Patient autonomy; Patient dependence
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Intracranial Hemorrhages; Hemorrhage; Subarachnoid Hemorrhage
• Other Study ID Numbers: 24_RIPH3-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No